SavedAdd your journal

Journals / Journal of Microbiology and Infectious Diseases / 2020 / Cilt: 10 - Sayı: 03

Current trends and possible therapeutic options against COVID-19

Uzair AHMED
Usman Ali ASHFAQ
Saba KHALİQ
Muhammad QASİM
Shah JAHAN
Muhammad Shareef MASOUD
Pages
110–120
Publication Date
2020-09-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Microbiol Infect Dis 2019; 9(3):110-120.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:COVID-19 is a highly contagious disease, caused by SARS-CoV-2, which can be transmitted from person to person.
📊
Key Findings & Data:SARS-CoV-2 has thought to be originated in bats and transmitted to humans.
💡
Conclusion & Impact:J Microbiol Infect Dis 2019; 9(3):110-120.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:SARS-CoV-2 · clinical features · therapeutic options

Abstract

COVID-19 is a highly contagious disease, caused by SARS-CoV-2, which can be transmitted from person to person. SARS-CoV-2 has thought to be originated in bats and transmitted to humans. SARS-CoV-2 has ssRNA genome that is about 30kb in length and it enters lung epithelial cells using spikes (S) by binding with Angiotensin‐converting enzyme 2 (ACE-2). Till date, there is no definitive treatment available for COVID-19 and currently, only symptomatic treatments are available. There is no vaccine developed to combat COVID-19 but scientists are working on developing different types of vaccines including nucleic acid vaccines, subunit vaccines and whole virus vaccines, that are effective and safe to use. Broad spectrum antivirals like ribavirin, lopinavir, ritonavir, arbidol, favipiravir, remdesivir are being test to lessen the viral load. Recently, ivermectin (anti-parasitic drug), has been administered in vitro and showed 99.8% reduction in SARS-CoV-2 in cultured cells in 48 hours. Convalescent plasma (CP) treatments are also being used in order to treat critical cases, nevertheless, no drug has been approved yet. This review focuses on the transmission, clinical features, prevention, current treatments and future possible approaches that can be used to develop therapeutic options against COVID-19. J Microbiol Infect Dis 2019; 9(3):110-120.

🔖

Cite This Article

AHMED, U., ASHFAQ, U. A., KHALİQ, S., QASİM, M., JAHAN, S., MASOUD, M. S. (2020). Current trends and possible therapeutic options against COVID-19. Journal of Microbiology and Infectious Diseases, Cilt: 10 - Sayı: 03, 110–120. https://ajindex.com/articles/83596

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Zumla A, Chan JFW, Azhar EI, et al. Coronaviruses-drug discovery and therapeutic options. Nature Reviews Drug Discovery 2016
  2. 327–347. 2.Chan JFW, Lau SKP, Woo PCY. The emerging novel Middle East respiratory syndrome coronavirus: The ‘knowns’ and ‘unknowns’. Journal of the Formosan Medical Association 2013
  3. 372–381. 3.Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunologic Research 2014
  4. 118–128. 4.Chan JFW, Lau SKP, To KKW, et al. Middle East Respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015
  5. 465–522. 5.Cheng VCC, Lau SKP, Woo PCY, et al. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clinical Microbiology Reviews 2007
  6. 660–694. 6.Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol 2015
  7. 185–195. 7.Drosten C, Günther S, Preiser W, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. N Engl J Med 2003
  8. 1967–1976. 8.Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Current Opinion in Virology 2015
  9. 123–129. 9.Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol 2020
  10. 491–494. 10. He F, Deng Y, Li W. Coronavirus Disease 2019 (COVID‐19): What we know? J Med Virol 2020
  11. 1–7. 11. WHO | World Health Organization, https://www.who.int/ (2020, accessed 2 April 2020). 12. COVID-19 Health Advisory Platform by Ministry of National Health Services Regulations and Coordination, http://covid.gov.pk/ (2020, accessed 5 April 2020). 13. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020
  12. 281–286. 14. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020
  13. 727–733. 15. Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020
  14. 270–273. 16. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020
  15. 565–574. 17. Li X, Zai J, Zhao Q, et al. Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2. J Med Virol 2020